---
title: "Understanding the Market | ANTENGENE-B rises over 6% after reaching a clinical collaboration with JUNSHI BIO to advance the joint exploration of ATG-037 and JS207"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276841515.md"
description: "ANTENGENE-B rose over 6%, as of the time of writing, up 6.4%, priced at HKD 3.66, with a transaction volume of HKD 13.326 million. In terms of news, ANTENGENE announced this morning that the company has reached a clinical cooperation agreement with JUNSHI BIO, and both parties will jointly explore the synergistic potential of ANTENGENE's ATG-037 (oral CD73 small molecule inhibitor) and JUNSHI BIO's JS207 (anti-PD-1/VEGF bispecific antibody) in combination therapy for cancer patients in mainland China. The company indicated that, in the context of immune checkpoint inhibitor (CPI) resistance becoming a significant clinical challenge, ATG-037 has demonstrated strong resistance reversal capabilities in combination with CPI in Phase I trials. This collaboration aims not only to validate the synergistic effects of the two innovative drugs but also to break through the existing efficacy ceiling of immunotherapy by employing a \"three-axis\" strategy of \"immunity + anti-angiogenesis + adenosine inhibition,\" striving for a significant extension of overall survival (OS) for cancer patients"
datetime: "2026-02-25T06:19:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276841515.md)
  - [en](https://longbridge.com/en/news/276841515.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276841515.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/276841515.md) | [繁體中文](https://longbridge.com/zh-HK/news/276841515.md)


# Understanding the Market | ANTENGENE-B rises over 6% after reaching a clinical collaboration with JUNSHI BIO to advance the joint exploration of ATG-037 and JS207

According to Zhitong Finance APP, ANTENGENE-B (06996) rose over 6%, currently up 6.4%, priced at HKD 3.66, with a transaction volume of HKD 13.326 million.

In terms of news, ANTENGENE announced this morning that the company has reached a clinical cooperation agreement with JUNSHI BIO. The two parties will jointly explore the synergistic potential of ANTENGENE's ATG-037 (oral CD73 small molecule inhibitor) and JUNSHI BIO's JS207 (anti-PD-1/VEGF bispecific antibody) in the combined treatment of cancer patients in mainland China.

The company stated that in the context of immune checkpoint inhibitor (CPI) resistance becoming a significant clinical challenge, ATG-037 has demonstrated strong resistance reversal capabilities when used in combination with CPI in Phase I trials. This collaboration aims not only to validate the synergistic effects of the two innovative drugs but also to break through the existing efficacy ceiling of immunotherapy through a "immune + anti-angiogenesis + adenosine inhibition" "three-axis" strategy, striving for a significant extension of overall survival (OS) for cancer patients

### Related Stocks

- [JUNSHI BIO (01877.HK)](https://longbridge.com/en/quote/01877.HK.md)
- [Junshi Biosciences (688180.CN)](https://longbridge.com/en/quote/688180.CN.md)
- [ANTENGENE-B (06996.HK)](https://longbridge.com/en/quote/06996.HK.md)

## Related News & Research

- [Shanghai Junshi Biosciences Schedules 2025 Results Briefing for Investor Q&A](https://longbridge.com/en/news/279928612.md)
- [20:30 ETAntengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs](https://longbridge.com/en/news/279507981.md)
- [Hong Kong February headline CPI +1.7% from year earlier](https://longbridge.com/en/news/279910332.md)
- [CSPC Pharma Gets China Nod for Obesity Drug Trial](https://longbridge.com/en/news/279944953.md)
- [Akeso’s AK120 Phase II Completion Adds New Momentum to Its Atopic Dermatitis Pipeline](https://longbridge.com/en/news/279466421.md)